Lectureship Awards

About Us_Lectureships_Banner

The International Association for the Study of Lung Cancer at its 2020 World Conference on Lung Cancer presented awards to clinicians and researchers who made significant contributions to the fight against lung cancer. The awards represent many major categories of lung cancer research, from tumor staging to tobacco control and smoking cessation.

2020 Lectureship Awards for Staging

The IASLC Lectureship Awards for Staging include:

  • Robert J. Ginsberg Lectureship Award for Surgery
  • Clifton F. Mountain Lectureship Award for Staging
  • Tsuguo Naruke Lectureship Award for Surgery

The award winners are selected by  the IASLC Staging and Prognostic Factors Committee chaired by Dr. Hisao Asamura, MD 

Image
Enrico Ruffini

Enrico Ruffini, MD

Full Professor, Department of Thoracic Surgery, University of Torino, Italy
Italy

Clifton F. Mountain Lectureship Award for Staging 

Image
Samina Park

Samina Park, MD

Clinical Assistant Professor; Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine

Tsuguo Naruke Lectureship Award for Surgery 

Image
Eric Lim

Eric Lim  MB, ChB, MD, MSc, FRCS(C-Th)

Consultant Thoracic Surgeon, Royal Brompton Hospital; Professor of Thoracic Surgery, Imperial College London

Robert J. Ginsberg Lectureship Award for Surgery 

Professor Eric Lim is a Consultant Thoracic Surgeon at the Royal Brompton Hospital and Professor of Thoracic Surgery at the National Heart and Lung Institute of Imperial College London. He received his undergraduate medical education at the University of Sheffield Medical School. His specialist heart and lung surgical training was at Papworth Hospital in Cambridge and the Royal Brompton Hospital in London. He spent time in medical research in Cambridge where he was awarded a Doctorate of Medicine and in research methods London where he received his Masters of Science in Medical Statistics funded by a UK Medical Research Council Scholarship.

Professor Lim is a sub-specialist in Thoracic Surgery with specific expertise in lung and other chest cancers. His technical expertise is minimally invasive (keyhole) surgery for lung cancer, pleural effusion, pneumothorax and other chest cancers, as well as complex surgery for advanced lung cancer involving airway and blood vessel reconstruction (to save as much normal lung as possible). 

He is the national chair for thoracic academia with an active interest in clinical trials serving as Chief Investigator for UK wide National Institute of Healthcare Research funded multicentre trials of surgery for mesothelioma (MARS 2) and VATS lobectomy (VIOLET). His translational research interest is focused on blood-based cancer diagnosis aspiring to shorten time to diagnosis and eliminate complications of invasive tissue biopsy.

His research has led to over 100 peer review publications, he has authored two award winning textbooks (Medicine and Surgery, Churchill’s Pocketbook of Differential Diagnosis) and 6 book chapters. Professor Lim chaired the British Thoracic Society and Society for Cardiothoracic Surgery’s Guidelines on the Management of Lung Cancer in 2010, contributed to the European Society of Medical Oncology Early Stage Lung Cancer Guidelines in 2013 and European Neuroendocrine Tumours Management of Bronchopulmonary Carcinoids Guidelines in 2014.

He also the Chair of the UK Thoracic Surgery Research Collaborative and served as a Councillor of the European Society of Thoracic Surgeons, a member of the Steering Committee of the British Thoracic Oncology Group, an Associate Editor of Thorax and the Deputy Statistics Editor for the Journal of Thoracic and Cardiovascular Surgery.
 

2020 Lectureship Nominating Committee Awards

The IASLC Lectureship Awards for the Nominating Committee include:

  • Daniel C. Ihde Lectureship Award for Medical Oncology 
  • Heine H. Hansen Lectureship Award for Small Cell Lung Cancer 

The award winners are selected by the IASLC Nominating Committee chaired by Dr. Giorgio Scagliotti 

Image
Lauren Byers

Lauren Averett Byers, MD

Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
United States

Heine H. Hansen Lectureship Award for Small Cell Lung Cancer 

Lauren Averett Byers, MD, MS is an Associate Professor in the Department of Thoracic and Head and Neck Medical Oncology and an Andrew Sabin Family Fellow at MD Anderson Cancer Center in Houston, Texas.  She completed her B.A. degree in Molecular Biology at Princeton University, her M.D. at Baylor College of Medicine, and M.S. in Patient-Based Research at the University of Texas Graduate School of Biomedical Sciences.  She is a member of the National Cancer Institute’s Small Cell Lung Cancer (SCLC) Consortium and serves on the NCI’s Thoracic Malignancy Steering Committee and SCLC Working Group. 

Dr. Byers’ laboratory is focused on the molecular profiling of small cell lung cancer and the development of new treatments and predictive biomarkers, particularly as they pertain to drugs targeting DNA damage repair (DDR) and immunotherapy. As a direct extension of work completed in her lab, she has led multiple clinical trials for patients with lung cancer. In addition to an outstanding publication record of over 100 peer reviewed manuscripts, Dr. Byers has earned multiple honors including two AACR The Best of AACR Journals Awards and the MD Anderson President’s Recognition for Faculty Excellence - Research Excellence Award.

As a physician-scientist, her landmark research led to the identification of fundamental differences in the molecular wiring of SCLC, including the identification of PARP1 and other DNA damage repair (DDR) proteins as novel therapeutic targets for SCLC.  Building on this, her group also identified a new role of DDR inhibitors in activating the innate immune system, whereby dramatically enhancing response to immune checkpoint blockade in preclinical models.  Recently, her team has defined molecularly distinct subtypes of SCLC that predict response to targeted therapy and immunotherapy and uncovered tumor heterogeneity as a driver of resistance using innovative, patient-derived models.    

Image
MyungJu Ahn

Myung-Ju Ahn, MD

Professor of Hemato-Oncology at the Department of Medicine, Sungkyunkwan University School of Medicine, Seoul.
South Korea

Daniel C. Ihde Lectureship Award for Medical Oncology 

Myung-Ju Ahn is Professor of Hemato-Oncology at the Department of Medicine, Sungkyunkwan University School of Medicine, Seoul. She is a member of numerous research associations and societies, including the ISLAC, AACR, and ASCO and is currently Chief of the Executive Committee and Chairperson of Lung Cancer Disease Committee of the KCSG. She is the current president of the KSMO and was chairperson of the multidisciplinary Immuno-oncology Study Group (2017–2018). She is a board member for the KCA, KSMO and KALC, and is on the editorial board of Journal of Thoracic Oncology. 
    
Prof Ahn received her medical and doctoral degrees from Hanyang University College of Medicine, Seoul and completed her residency training at Hanyang University Hospital. She has held numerous research fellowships, including a postdoctoral research fellowship at the Memorial Sloan-Kettering Cancer Center, New York, and has authored over 250 cancer research publications. Her research interests include the development of predictive and prognostic markers for personalised lung cancer therapy. She has recently focused on early clinical trials for the development of drug discovery and reposition of targeted drugs and the development of a NSCLC genome atlas. Her accolades for her dedication to cancer research include Best Researcher Award, KMWA (2003); Best Researcher Award, KACO (2015); Boryoung Scientific Award, Korean Cancer Research Foundation (2018), and Highly Cited Researcher, Clavirate analytics (2019).
 

2020 Lectureship Nurses and Allied Health Professionals Award Winners

The 2020 Lectureship Awards for Nurses and Allied Health Professionals include: 

  • IASLC Lectureship Award for Nurses and Allied Health Professionals 
  • James D. Cox Lectureship Award for Radiation Oncology 
  • IASLC Lectureship Award for Tobacco Control and Smoking Cessation 

The award winners are selected by the IASLC Nurses and Allied Health Professionals Committee Chaired by Dr. Melissa Culligan 

Image
Mary Duffy

Mary Duffy, RSCN, RGN, RSM

Clinical Nurse Consultant/Lung Cancer Specialist
Australia

IASLC Lectureship Award for Nurses and Allied Health Professionals 

Mary Duffy is the Advanced Practice Clinical Nurse Consultant  for the Lung Service at the Peter Mac Callum Cancer Centre and works primarily with patients who have lung cancer or mesothelioma, and their families.
 
Mary has worked with lung cancer patients for over 20 years in a variety of roles. Her areas of professional   interest include all aspects of supportive care for people with lung cancer and mesothelioma, including symptom management, advocacy, patient and carer information and support.
 
Mary has completed a Masters of Philosophy by Nursing Research at The University of Melbourne. She is an active member of, both national and international, nursing and lung cancer professional organisations and is the inaugural Chairperson of the Australia and New Zealand Lung Cancer Nurses Forum (ANZ-LCNF).
 

Image
Wanda de Kanter Koppenol

Wanda de Kanter-Koppenol, MD

Chest physician Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
Netherlands

IASLC Lectureship Award for Tobacco Control and Smoking Cessation 

Dr. de Kanter-Koppenol a lung specialist mainly working in the lung cancer field as an oncologist and as a patient advocate (consultant lung cancer organization for many years) 

She is also a “preventionist” who is trained in motivational interviewing and founded the biggest smoking cessation clinic in the Netherlands. She is a member of the Smoke free Generation Network.

She is also an activist: primary prevention is crucial: because the nicotine addiction is severe, most people die due to a smoking related disease before then can quit or they quit to late.  She focuses on the tobacco industry lobby in The Hague, politicians and on the tobacco industry itself by lawsuits, (inter) national lectures and ( social) media. They are part of the smoke free generation network: creating smoke free hospitals and all other health departments, including the addiction and psychiatry care. 

Their main focus is tax increase and a decrease in points of sale. Recently this was settled: in 2024 supermarkets are not allowed anymore to sell cigarettes.
 

Image
Walter John Curran, Jr., M.D.

Walter John Curran, Jr., MD, FACR, FASCO

NRG Oncology Presiding Chairman
United States

James D. Cox Lectureship Award for Radiation Oncology 

For the past several decades, Dr. Curran has focused on the conduct of clinical and translational cancer research at the institutional and national cooperative or network group level. He has served as Executive Director of Winship Cancer Institute (Winship) since 2009 and has successfully led Winship to align its cancer care and cancer prevention efforts with its research and education programs, all with the mission of lessening the cancer burden in the state of Georgia. Winship was approved as the latest NCI-designated comprehensive cancer center effective April 1, 2017.

He has also had the great honor to also serve as one of the founding leaders of NRG Oncology, which began its activities as an NCI-supported NCTN network group in 2014. NRG Oncology seeks to improve the duration and quality of lives of adults with non-hematologic malignancies through the conduct of science-driven, NCI-supported multi-institutional clinical trials. His role as an NRG Oncology leader provides an opportunity to integrate outstanding science of cancer investigators everywhere with the national and international reach of a large NCI-supported network group. NRG Oncology focuses on patients with malignancies which disproportionately affect minority patients, and these include the gender-specific malignancies of gynecologic, prostate, or breast cancers as well as brain tumors or head and neck, lung, or gastrointestinal cancers. In its first five years of activity, NRG Oncology has been extraordinarily productive in terms of publications, clinical trial activation and enrollment, and influence on practice standards. His role as one of the three NRG Oncology Group Chairmen requires a highly collaborative interaction with the NRG Oncology investigators, and he looks forward with great anticipation to working with Drs Jordan and his colleagues on projects involving the resources of the NRG Oncology Biospecimen Resources and the NRG Oncology research themes.

2020 Lectureship Award for Pathology Committee

The Lectureship Award for the Pathology Committee is:

  • Fred R. Hirsch Lectureship Award for Translational Research 

In its innagural year the award winner was selected by the Pathology Committee chaired by Dr. Keith Kerr. 

Image
Sanja Dacic, MD, PhD

Sanja Dacic, MD, PhD

Professor of pathology in the Department of Pathology at the University of Pittsburgh , Director of Anatomic Pathology at UPMC Presbyterian Hospital and Director of Thoracic Pathology Center of Excellence
United States

Fred R. Hirsch Lectureship Award for Translational Research (inaugural year) 

Sanja Dacic, MD, PhD, is a professor of pathology in the Department of Pathology at the University of Pittsburgh , Director of Anatomic Pathology at UPMC Presbyterian Hospital and Director of Thoracic Pathology  Center of Excellence . Dr Dacic received her medical degree and a doctor of philosophy degree at the School of Medicine, University of Zagreb, in Zagreb, Croatia. She completed her residency training at the University of Pittsburgh and joined the faculty immediately after her fellowship in surgical pathology. Dr. Dacic is focused on diagnostic pulmonary and molecular pathology and has been involved in many basic and translational research projects in lung cancer and pleural mesotheliomas that have resulted in numerous peer-reviewed scientific articles, book chapters, and reviews.  She was a co-author of the original and revised CAP/IASLC/ AMP guidelines for molecular testing in lung cancer. Dr. Dacic is a member of the Editorial Board for the upcoming  5th WHO Classification of Thoracic Tumors. She is a deputy editor in chief of Archives of Pathology & Laboratory Medicine

She was elected to the Board of the United States and Canadian Academy of Pathology (USCAP)  for three years (2015-2018) . She has been an officer of the Pulmonary Pathology Society since 2006 and is currently serving as president. Dr. Dacic is a member of the US and Canadian Mesothelioma Group and the  International Mesothelioma Panel. She has been a member of the IASLC Pathology Committee since 2010. Dr. Dacic contributed to the last seven WCLC meeting, including as invited faculty. 
 

Past Lectureship Award Winners

  • Corinne Favire-Finn, FRCR, MD, PhD - James D. Cox Lectureship Award for Radiation Oncology 
  • Roman K. Thomas, MD - Adi F. Gazdar Lectureship Award for Translational Science 
  • Giulia Veronesi, MD - Robert J. Ginsberg Lectureship Award for Surgery 
  • Caroline Dive, MD, PhD - Heine H. Hansen Lectureship Award for Small Cell Lung Cancer 
  • Kahren M. White - IASLC Lectureship Award for Nursing and Allied Health Professionals 
  • Emily Stone, MD - IASLC Lectureship Award for Tobacco Control and Smoking Cessation 
  • Daniel Tan, MD - Daniel C. Ihde Lectureship Award for Medical Oncology 
  • Paula A. Ugalde, MD - Clifton F. Mountain Lectureship Award for Staging 
  • Raja M. Flores, MD - Tsuguo Naruke Lectureship Award for Surgery